» Articles » PMID: 30403697

Catecholaminergic Polymorphic Ventricular Tachycardia Patients with Multiple Genetic Variants in the PACES CPVT Registry

Abstract

Background: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is often a life-threatening arrhythmia disorder with variable penetrance and expressivity. Little is known about the incidence or outcomes of CPVT patients with ≥2 variants.

Methods: The phenotypes, genotypes and outcomes of patients in the Pediatric and Congenital Electrophysiology Society CPVT Registry with ≥2 variants in genes linked to CPVT were ascertained. The American College of Medical Genetics & Genomics (ACMG) criteria and structural mapping were used to predict the pathogenicity of variants (3D model of pig RyR2 in open-state).

Results: Among 237 CPVT subjects, 193 (81%) had genetic testing. Fifteen patients (8%) with a median age of 9 years (IQR 5-12) had ≥2 variants. Sudden cardiac arrest occurred in 11 children (73%), although none died during a median follow-up of 4.3 years (IQR 2.5-6.1). Thirteen patients (80%) had at least two RYR2 variants, while the remaining two patients had RYR2 variants plus variants in other CPVT-linked genes. Among all variants identified, re-classification of the commercial laboratory interpretation using ACMG criteria led to the upgrade from variant of unknown significance (VUS) to pathogenic/likely pathogenic (P/LP) for 5 variants, and downgrade from P/LP to VUS for 6 variants. For RYR2 variants, 3D mapping using the RyR2 model suggested that 2 VUS by ACMG criteria were P/LP, while 2 variants were downgraded to likely benign.

Conclusions: This severely affected cohort demonstrates that a minority of CPVT cases are related to ≥2 variants, which may have implications on family-based genetic counselling. While multi-variant CPVT patients were at high-risk for sudden cardiac arrest, there are insufficient data to conclude that this genetic phenomenon has prognostic implications at present. Further research is needed to determine the significance and generalizability of this observation. This study also shows that a rigorous approach to variant re-classification using the ACMG criteria and 3D mapping is important in reaching an accurate diagnosis, especially in the multi-variant population.

Citing Articles

Clinical Characteristics, Genetic Basis and Healthcare Resource Utilisation and Costs in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia: A Retrospective Cohort Study.

Chung C, Lee S, Zhou J, Chou O, Lee T, Leung K Rev Cardiovasc Med. 2024; 23(8):276.

PMID: 39076628 PMC: 11266943. DOI: 10.31083/j.rcm2308276.


Precision medicine in catecholaminergic polymorphic ventricular tachycardia: Recent advances toward personalized care.

Siu A, Tandanu E, Ma B, Osas E, Liu H, Liu T Ann Pediatr Cardiol. 2024; 16(6):431-446.

PMID: 38817258 PMC: 11135882. DOI: 10.4103/apc.apc_96_23.


Catecholaminergic Polymorphic Ventricular Tachycardia: Clinical Characteristics, Diagnostic Evaluation and Therapeutic Strategies.

Aggarwal A, Stolear A, Alam M, Vardhan S, Dulgher M, Jang S J Clin Med. 2024; 13(6).

PMID: 38542006 PMC: 10971616. DOI: 10.3390/jcm13061781.


Patient-specific induced pluripotent stem cell properties implicate Ca-homeostasis in clinical arrhythmia associated with combined heterozygous and variants.

Zhou Y, Huang W, Liu L, Li A, Jiang C, Zhou R Philos Trans R Soc Lond B Biol Sci. 2023; 378(1879):20220175.

PMID: 37122207 PMC: 10150201. DOI: 10.1098/rstb.2022.0175.


Clinical Characteristics, Genetic Findings and Arrhythmic Outcomes of Patients with Catecholaminergic Polymorphic Ventricular Tachycardia from China: A Systematic Review.

Leung J, Lee S, Zhou J, Jeevaratnam K, Lakhani I, Radford D Life (Basel). 2022; 12(8).

PMID: 35892906 PMC: 9330865. DOI: 10.3390/life12081104.


References
1.
Francia P, Adduci C, Semprini L, Stanzione R, Serdoz A, Caprinozzi M . RyR2 Common Gene Variant G1886S and the Risk of Ventricular Arrhythmias in ICD Patients with Heart Failure. J Cardiovasc Electrophysiol. 2015; 26(6):656-61. DOI: 10.1111/jce.12658. View

2.
Priori S, Wilde A, Horie M, Cho Y, Behr E, Berul C . Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm. 2013; 10(12):e85-108. DOI: 10.1016/j.hrthm.2013.07.021. View

3.
Giudicessi J, Roden D, Wilde A, Ackerman M . Classification and Reporting of Potentially Proarrhythmic Common Genetic Variation in Long QT Syndrome Genetic Testing. Circulation. 2018; 137(6):619-630. PMC: 6383807. DOI: 10.1161/CIRCULATIONAHA.117.030142. View

4.
Lieve K, Verkerk A, Podliesna S, van der Werf C, Tanck M, Hofman N . Gain-of-function mutation in SCN5A causes ventricular arrhythmias and early onset atrial fibrillation. Int J Cardiol. 2017; 236:187-193. DOI: 10.1016/j.ijcard.2017.01.113. View

5.
Roston T, Yuchi Z, Kannankeril P, Hathaway J, Vinocur J, Etheridge S . The clinical and genetic spectrum of catecholaminergic polymorphic ventricular tachycardia: findings from an international multicentre registry. Europace. 2017; 20(3):541-547. PMC: 6059141. DOI: 10.1093/europace/euw389. View